Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Follow-On Protein Meeting Sheds More Light On Topic

March 2, 2005

By Aaron Lorenzo

Diabetes Drug Glumetza Gets Approvable Letter From FDA

March 2, 2005

By Aaron Lorenzo

The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)

Follow-On Protein Meeting Sheds More Light On Topic

March 2, 2005

By Aaron Lorenzo

Diabetes Drug Glumetza Gets Approvable Letter From FDA

March 2, 2005

By Aaron Lorenzo

The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)

Bill On Stem Cells Referred To Subcommittee Of House

Feb. 28, 2005

By Aaron Lorenzo

Bill On Stem Cells Referred To Subcommittee Of House

Feb. 28, 2005

By Aaron Lorenzo

Pharsight Software Used For FDA's Critical Path Initiative

Feb. 25, 2005

By Aaron Lorenzo

Pharsight Software Used For FDA's Critical Path Initiative

Feb. 25, 2005

By Aaron Lorenzo

N.Y. Trade Association Pushing For State Biotechnology Backing

Feb. 24, 2005

By Aaron Lorenzo

N.Y. Trade Association Pushing For State Biotechnology Backing

Feb. 24, 2005

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...